Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07322679 · ClinicalTrials.gov registry record · NA
Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults
A NA study, sponsored by Nanjing Nutrabuilding Bio-tech Co..
- Not yet
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT07322679: Clinical Trial NA study, sponsored by Nanjing Nutrabuilding Bio-tech Co..
NCT07322679 is a NA study that has not yet begun recruiting, run by Nanjing Nutrabuilding Bio-tech Co.. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07322679, a NA study, has not yet begun recruiting, sponsored by Nanjing Nutrabuilding Bio-tech Co..
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate whether dihydroberberine (DHB) supplementation can improve body composition, blood sugar control, energy levels, appetite, and mood in healthy adults with overweight or mild obesity. The study focuses on men and women aged 35-55 years with a BMI between 27.0 and 33.0 kg/m². The main questions it aims to answer are: Does daily DHB supplementation lead to greater reductions in body weight over 12 weeks compared to placebo? Does DHB improve glycemic responses, appetite regulation, energy levels, and mood, both acutely (short-term) and chronically (over 12 weeks)? Researchers will compare two groups-one receiving DHB (400 mg/day) and the other receiving a placebo-administered as two capsules twice daily for 12 weeks. Participants will: Attend three in-clinic visits over approximately 14 weeks (including screening, baseline, and week 12 visits) Undergo mixed-meal tolerance tests (MTTs) to assess glucose metabolism, appetite, and energy levels Complete body composition assessments (including DXA scans), blood tests (e.g., glucose, insulin, HbA1c), and mood questionnaires (POMS-2) Be monitored for safety throughout the study
Primary Outcome
Body weight will be measured in-clinic at Baseline (Visit 2, Week 0, Day 1) and End of Study (Visit 3, Week 12, Day 84) using a calibrated digital scale under standardized conditions (fasted, light clothing, no shoes).
Interventions
- DIETARY_SUPPLEMENT Placebo （Microcrystalline Cellulose）
- DIETARY_SUPPLEMENT Dihydroberberine（DHB）
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-09-25 |
| Phase | NA |
What is known before NCT07322679 opens enrollment
NCT07322679 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo （Microcrystalline Cellulose） is the first listed.
NCT07322679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07322679 about?
NCT07322679 is a clinical study titled "Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults". The goal of this clinical trial is to evaluate whether dihydroberberine (DHB) supplementation can improve body composition, blood sugar control, energy levels, appetite, and mood in healthy adults with overweight or mild obesity. The study focuses on men and women aged 35-55 years with a BMI between...
What is the current status of trial NCT07322679?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-12-15. Estimated completion is 2026-09-25.
What interventions are being tested in trial NCT07322679?
The interventions under investigation include: Placebo （Microcrystalline Cellulose） (DIETARY_SUPPLEMENT), Dihydroberberine（DHB） (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07322679?
This trial is sponsored by Nanjing Nutrabuilding Bio-tech Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07322679's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI